Trend Macrolytics, LLC
Donald Luskin, Chief Investment Officer
Thomas Demas, Managing Director
Michael Warren, Energy Strategist

# Data Insights: Covid-2019 Monitor

Wednesday, July 21, 2021

## The global scorecard

**The worst ten countries**

| New cases | | New Deaths | |
|---|---|---|---|
| United Kingdom | +46,688 | Ecuador | +8,786 |
| United States | +42,703 | India | +3,998 |
| India | +42,015 | Kazakhstan | +1,504 |
| Indonesia | +38,325 | Brazil | +1,424 |
| Brazil | +27,592 | Indonesia | +1,280 |
| Iran | +27,444 | Russia | +771 |
| Spain | +27,286 | South Africa | +596 |
| Russia | +23,234 | Argentina | +426 |
| France | +18,217 | Colombia | +378 |
| Kazakhstan | +15,663 | Mexico | +341 |
| | +309,167 | | +19,504 |
| World | +529,526 | World | +22,249 |
| Top ten | 58% | Top ten | 88% |







Source: Johns Hopkins, TrendMacro calculations

**For more information contact us:**
Donald Luskin: 312 273 6766 don@trendmacro.com
Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

# The US scorecard

**The ten worst US states**

| New cases | | New Deaths | | New in hospital | | Cume cases | | Cume deaths | | Cume in hospital | | Hospital use | | ICU use | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CA | +9,765 | MO | +41 | FL | +206 | CA | 3,875,420 | CA | 64,144 | TX | 260,020 | RI | 89% | MO | 27% |
| FL | +6,493 | FL | +34 | TX | +100 | TX | 3,049,688 | NY | 53,784 | CA | 244,496 | MA | 85% | AR | 23% |
| TX | +5,616 | TX | +26 | CA | +80 | FL | 2,448,505 | TX | 52,865 | FL | 196,191 | MD | 85% | NV | 22% |
| MO | +2,116 | LA | +20 | GA | +55 | NY | 2,128,710 | FL | 38,350 | NY | 137,570 | MO | 84% | UT | 20% |
| AR | +1,875 | AL | +17 | LA | +48 | IL | 1,403,508 | PA | 27,805 | GA | 111,387 | PA | 82% | WY | 17% |
| GA | +1,569 | MI | +15 | AL | +43 | PA | 1,221,836 | NJ | 26,557 | PA | 92,342 | FL | 81% | MS | 15% |
| LA | +1,562 | WA | +13 | AZ | +33 | GA | 1,150,835 | IL | 25,816 | OH | 88,864 | CT | 81% | FL | 14% |
| AL | +1,391 | NJ | +12 | NY | +28 | OH | 1,118,513 | GA | 21,571 | IL | 83,639 | NV | 81% | TX | 13% |
| MI | +1,198 | OH | +12 | NV | +24 | NJ | 1,029,901 | MI | 21,124 | KY | 80,000 | DC | 81% | OK | 13% |
| AZ | +1,154 | CA | +11 | UT | +23 | NC | 1,026,697 | OH | 20,449 | MI | 73,744 | MN | 80% | ID | 13% |
| | +32,739 | | +201 | | +640 | | 18,453,613 | | 352,465 | | 1,368,253 | | | | |
| All states | +49,196 | | +332 | | +611 | All states | 34,174,774 | | 609,529 | | 2,437,679 | All states | 70% | | 67% |
| Top ten | 67% | | 61% | | 105% | Top ten | 54% | | 58% | | 56% | Median | 73% | | 5% |

*Some states not reporting*

**Five most improved US states**

| Fewer daily cases | | Fewer new deaths | | Fewer new hospitalizations | | Most pop immunity growth | |
|---|---|---|---|---|---|---|---|
| LA | -2,425 | CA | -28 | KY | -364 | MP | +70 bp |
| NC | -2,079 | AR | -15 | AR | -57 | UT | +20 bp |
| IL | -2,072 | IL | -14 | OH | -44 | AZ | +10 bp |
| MS | -1,753 | KY | -14 | MO | -33 | CO | +10 bp |
| GA | -1,721 | IN | -6 | MS | -24 | DE | +10 bp |




Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

# Rolling out the vaccines in the US and the world

| US overall | Total | | | | Today |
|---|---|---|---|---|---|
| Doses distributed | 402,635,565 | | | | +0.555 million |
| Doses administered | 348,267,725 | | | | +0.127 million |
| **Administered** | **One dose** | **% Pop** | **Immune** | **% pop** | **New immune today** |
| Total population | 191,188,798 | 57% | 165,874,181 | 50% | +0.140 million |
| Age 12 to 17 | 9,888,565 | 39% | 7,748,010 | 31% | +0.036 million |
| Age 18 to 64 | 130,730,306 | 64% | 112,993,317 | 56% | +0.091 million |
| Age 65 and over | 50,347,513 | 92% | 45,003,704 | 82% | +0.013 million |

| Immunity | Full | Partial |
|---|---|---|
| US | 48.3% | 55.8% |
| UK | 53.4% | 68.3% |
| France | 42.1% | 56.0% |
| Spain | 52.1% | 63.5% |
| Germany | 46.9% | 59.8% |
| Italy | 45.0% | 60.8% |
| Australia | 11.4% | 29.0% |
| Israel | 60.7% | 66.4% |
| Canada | 51.5% | 70.4% |
| Japan | 23.2% | 35.3% |
| Africa | 1.5% | 3.1% |
| India | 6.3% | 23.8% |
| Brazil | 16.5% | 45.0% |

Global data differs from sources, timing

China NA




At today's dosing pace, every American >18 immune in

**1006 days**

by Apr 22, 2024

61.2% of population >18 immunized

11.6% previously tested positive

**72.8%** vs 60% adult herd immunity*

| State |
|---|
| Immunities distributed as % population** |
| At least partial immunity as % population |
| Full immunity as % population |

Best

Middle

Worst

| AK | | |
|---|---|---|
| 61.7% | 50.7% | 45.0% |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | WI | | | | VT | NH |
| | | | | | 56.4% | | | | 79.3% | 73.4% |
| | | | | | 54.8% | | | | 75.0% | 64.0% |
| | | | | | 51.2% | | | | 67.0% | 57.8% |
| WA | ID | MT | ND | MN | IL | MI | | NY | MA | |
| 66.2% | 51.0% | 55.9% | 50.1% | 61.9% | 62.5% | 62.3% | | 66.3% | 74.9% | |
| 63.0% | 40.4% | 48.6% | 44.6% | 58.0% | 61.1% | 52.4% | | 61.8% | 71.7% | |
| 56.7% | 36.9% | 43.9% | 39.6% | 53.2% | 47.8% | 48.3% | | 56.1% | 63.2% | |
| OR | NV | WY | SD | IA | IN | OH | PA | NJ | CT | RI |
| 71.5% | 54.7% | 48.0% | 58.5% | 58.9% | 54.0% | 56.7% | 66.5% | 70.0% | 71.1% | 75.5% |
| 59.9% | 52.0% | 40.7% | 51.6% | 52.4% | 46.3% | 49.1% | 64.4% | 64.6% | 68.6% | 66.0% |
| 55.3% | 43.5% | 36.0% | 46.3% | 49.1% | 43.6% | 45.9% | 51.4% | 57.2% | 62.4% | 60.6% |
| CA | UT | CO | NE | MO | KY | WV | VA | MD | DE | |
| 66.6% | 54.2% | 65.0% | 57.7% | 54.0% | 54.2% | 56.8% | 65.3% | 75.1% | 70.5% | |
| 63.4% | 50.9% | 59.3% | 52.8% | 46.8% | 50.8% | 45.8% | 60.6% | 63.5% | 59.6% | |
| 51.8% | 44.0% | 53.6% | 48.9% | 40.3% | 44.8% | 38.8% | 53.7% | 57.9% | 51.9% | |
| | AZ | NM | KS | AR | TN | NC | SC | DC | | |
| | 60.1% | 60.7% | 57.1% | 51.1% | 50.3% | 59.8% | 55.5% | 80.3% | | |
| | 51.9% | 64.3% | 50.4% | 44.2% | 43.5% | 50.0% | 45.5% | 63.0% | | |
| | 44.6% | 56.3% | 43.1% | 35.4% | 38.5% | 43.1% | 40.0% | 54.0% | | |
| | | | OK | LA | MS | AL | GA | | | |
| | | | 54.3% | 47.2% | 48.5% | 53.1% | 56.6% | | | |
| | | | 46.3% | 40.0% | 38.0% | 41.3% | 44.9% | | | |
| | | | 39.6% | 36.2% | 33.9% | 33.7% | 37.9% | | | |
| HI | | | TX | | | | | FL | | PR |
| 72.2% | | | 59.3% | | | | | 63.2% | | 69.4% |
| 70.7% | | | 49.9% | | | | | 55.7% | | 67.7% |
| 53.0% | | | 43.0% | | | | | 47.9% | | 58.7% |

As of Jul 21

* Includes persons >18 fully immunized or previosuly tested positive, no overlap. Disregards untested positives, natural immunities.

** One dose of Pfizer/Moderna counts as half an immunity, one dose of J&J as a full immunity

Source: CDC, CDC, Our World in Data, TrendMacro calculations

# US deep-dive

National and state-by-state data do not line up because of different sources




























Source: Johns Hopkins, Covid Act Now, TrendMacro calculations

## US deep-dive on the demographics of age, race and health

*Updates weekly on Sundays*

### Age distribution of US cases, fatalities and case-fatality rates

Cumulative




### Racial distribution of US cases, fatalities and case-fatality rates

Cumulative




### Comorbidities

Top-ten joint causes of Covid mortalities, cumulative




As of Jul 11

For over 5% of these deaths, COVID-19 was the only cause mentioned on the death certificate. For deaths with conditions or causes in addition to COVID-19, on average, there were 4.0 additional conditions or causes per death.

Source: Distributions CDC, Comorbidities CDC, TrendMacro calculations

## Recommended reading

Fauci Rebukes Rand Paul for Threatening Him With Prison in Fiery Clash: 'You Do Not Know What You Are Talking About!'
Rudy Takala
*Mediaite*
July 20, 2021

On Fox News, Vaccination Pleas Intensify, but Skepticism Persists
Michael M. Grynbaum, Tiffany Hsu and Zolan Kanno-Youngs
*New York Times*
JJuly 20, 2021

Vallance corrects mistake to say 60% of people being admitted to hospital with coronavirus are unvaccinated
*Sky News*
July 20, 2021

Natural infection vs vaccination: Which gives more protection?
David Rosenberg
*Arutz Shiva*
July 13, 2021

Why People Feel Like Victims
Mark MacNamara
*Nautilus*
May 5, 2021

## Meme of the day

Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP

## The coronavirus case accelerometer… tracking the world's infection curves

*Share of infected population from first day with 100 confirmed cases, log scale*




Source: Johns Hopkins, TrendMacro calculations

## The coronavirus mortality accelerometer … tracking the world's fatality curves

*Share of deceased population from day of first fatality, log scale*




Source: Johns Hopkins, TrendMacro calculations

## "Exponential"? Our most reliable evidence of the rate of spread of Covid-2019

*Vertical: days to double deaths  Horizontal: days from first death*

Flat indicates exponential spread  Declining indicates supra-exponential spread  Rising indicates sub-exponential spread




Source: Johns Hopkins, TrendMacro calculations

Requirement to Open Up America Again: 14-day "downward trajectory" in new cases

*14-day moving average, last 14 days  Most recent value displayed* • High • Low

Downward trajectory  Five best  Upward trajectory  Five worst

Source: Johns Hopkins, TrendMacro calculations

## Alt requirement to Open Up America Again: 14-day "downward trajectory" in pos tests

*14-day moving average, last 14 days* *Most recent value displayed* • High • Low

Downward trajectory Five best Upward trajectory Five worst




Source: Covid Act Now, TrendMacro calculations

## From Ground Zero to the Rio Grande




Source: Johns Hopkins, TrendMacro calculations

# The sun-belt hot-spot states (other than Texas)




Source: Johns Hopkins, TrendMacro calculations

## Patient zero… and then everyone else




Source: Johns Hopkins, TrendMacro calculations

## Impact in the largest economies




Source: Johns Hopkins, TrendMacro calculations

## Impact in The Anglosphere




Source: Johns Hopkins, TrendMacro calculations

## Impact in continental Europe




Source: Johns Hopkins, TrendMacro calculations

## Impact in other hot-spots




Source: Johns Hopkins, TrendMacro calculations

## Impact in the BRICs ex-China




Source: Johns Hopkins, TrendMacro calculations

## Impact in the Middle East and Africa




Source: Johns Hopkins, TrendMacro calculations

## Impact in Africa, continued




Source: Johns Hopkins, TrendMacro calculations